FindTrial
Sign In

FF MDI 9.6 μg

DRUG2 trials

Sponsors

Pearl Therapeutics, Inc.

Conditions

Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disorder

Phase 2

Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT02196077
Pearl Therapeutics, Inc.Chronic Obstructive Pulmonary Disease
Start: 2014-08-01End: 2015-03-01Updated: 2018-06-20

Phase 3

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
CompletedNCT02766608
Pearl Therapeutics, Inc.Chronic Obstructive Pulmonary Disorder
Start: 2016-05-31End: 2017-12-01Updated: 2019-09-24

Related Papers

Predictive modeling of COPD exacerbation rates using baseline risk factors
Therapeutic Advances in Respiratory Disease2022-01-0124 citations
Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
ERJ Open Research2020-04-018 citations
Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies
2019-09-28
Efficacy and safety of budesonide/formoterol fumarate dihydrate metered dose inhaler (BFF MDI) using co-suspension delivery technology compared to monocomponents and an active comparator in COPD
2018-09-15
Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study
European Respiratory Journal2018-09-0121 citations
Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
2018-05-082 citations
Benefit of FDC budesonide (BUD) and formoterol fumarate (FF) FDC delivered by a novel MDI co-suspension technology (BFF MDI), in patients (pts) with moderate-to-severe COPD
2016-09-01